Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A T1 Translational Multicenter Randomized Phase II Study of Temsirolimus Versus Cetuximab Plus Temsirolimus in Patients With Recurrent / Metastatic Head and Neck Cancer, Who Failed Prior EGFR Based Therapy

NCT01256385 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01256385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01256385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A T1 Translational Multicenter Randomized Phase II Study of Temsirolimus Versus Cetuximab Plus Temsirolimus in Patients With Recurrent / Metastatic Head and Neck Cancer, Who Failed Prior EGFR Based Therapy
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
December 31, 2013
Enrollment
86 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent hypopharyngeal squamous cell carcinoma, recurrent laryngeal squamous cell carcinoma, recurrent laryngeal verrucous carcinoma, recurrent lip and oral cavity squamous cell carcinoma, recurrent metastatic squamous cell carcinoma in the neck with occult primary, recurrent nasal cavity and paranasal sinus squamous cell carcinoma, recurrent nasopharyngeal keratinizing squamous cell carcinoma, recurrent oral cavity verrucous carcinoma, recurrent oropharyngeal squamous cell carcinoma, recurrent salivary gland carcinoma, salivary gland squamous cell carcinoma, squamous cell carcinoma metastatic in the neck with occult primary, stage iv hypopharyngeal squamous cell carcinoma, stage iv nasopharyngeal keratinizing squamous cell carcinoma, stage iva laryngeal squamous cell carcinoma, stage iva laryngeal verrucous carcinoma, stage iva lip and oral cavity squamous cell carcinoma, stage iva major salivary gland carcinoma, stage iva nasal cavity and paranasal sinus squamous cell carcinoma, stage iva oral cavity verrucous carcinoma, stage iva oropharyngeal squamous cell carcinoma, stage ivb laryngeal squamous cell carcinoma, stage ivb laryngeal verrucous carcinoma, stage ivb lip and oral cavity squamous cell carcinoma, stage ivb major salivary gland carcinoma, stage ivb nasal cavity and paranasal sinus squamous cell carcinoma, stage ivb oral cavity verrucous carcinoma, stage ivb oropharyngeal squamous cell carcinoma, stage ivc laryngeal squamous cell carcinoma, stage ivc laryngeal verrucous carcinoma, stage ivc lip and oral cavity squamous cell carcinoma, stage ivc major salivary gland carcinoma, stage ivc nasal cavity and paranasal sinus squamous cell carcinoma, stage ivc oral cavity verrucous carcinoma, stage ivc oropharyngeal squamous cell carcinoma, tongue carcinoma